Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132
HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127
Disc Medicine Enters Sales Agreement With TD Cowen For Common Stock Offering; May Offer Common Stock Up To $189.93M Through TD Cowen
Disc Medicine (NASDAQ:IRON) Q3 2026: Narrower Loss and Pipeline Catalysts Strengthen the Outlook
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Disc Medicine Q3 EPS $(1.53) Beats $(1.76) Estimate
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124
Wedbush Maintains Outperform on Disc Medicine, Raises Price Target to $110
Disc Medicine: APOLLO Changes The Story, But How Much Upside Remains
Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan
Disc Medicine (IRON) APOLLO Win Puts Its Valuation Discount Back In Focus
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
What Could Disc Medicine (IRON) Reveal From Its Phase 3 APOLLO Trial?
Disc’s once-spurned rare disease drug to get a second chance at approval
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.